Gene therapy could free blood disease patients from transfusions

NCT ID NCT07489196

First seen Mar 27, 2026 · Last updated May 12, 2026 · Updated 7 times

Summary

This study tests a single dose of CS-101, a gene therapy, in 20 people aged 12 to 35 with β-thalassemia major, a severe blood disorder requiring regular transfusions. The goal is to see if it is safe and can help patients produce enough healthy hemoglobin to stop needing transfusions for at least 12 months. Participants will be monitored for side effects and blood cell recovery after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Β-THALASSEMIA MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

  • Ruijin Hospital Shanghai JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.